Parallax Health Sciences, Inc. (PRLX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Parallax Health Sciences, Inc. (PRLX) trades at $0.0001. Parallax Health Sciences, Inc. is a healthcare technology company focused on developing integrated digital healthcare solutions. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for PRLX: PRLX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PRLX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PRLX: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Parallax Health Sciences, Inc. (PRLX) Healthcare & Pipeline Overview
Parallax Health Sciences, Inc. leverages advanced technology to create an integrated digital healthcare network, offering remote monitoring, diagnosis, and treatment solutions that address chronic illnesses, enhancing patient care and provider communication.
What Is the Investment Thesis for PRLX?
Parallax Health Sciences, Inc. presents a unique investment thesis driven by its innovative product offerings and the growing demand for digital healthcare solutions. The company operates in a market projected to reach $500 billion by 2028, with a significant focus on chronic disease management, which represents a substantial revenue opportunity. With a gross margin of 86.9%, Parallax demonstrates strong profitability potential, although its current profit margin indicates challenges in operational efficiency. The ongoing development of its REBOOT and Target System technologies could serve as key growth catalysts, potentially increasing market share and revenue streams. However, investors may want to evaluate the inherent risks associated with regulatory approvals and market competition as the company seeks to expand its footprint in the healthcare sector.
Based on FMP financials and quantitative analysis
PRLX Key Highlights
Gross margin of 86.9% indicates strong profitability potential despite current operational challenges.
- P/E ratio of -0.00 reflects ongoing financial difficulties, necessitating careful evaluation of recovery prospects.
- The company employs a lean workforce of 9, which may limit operational scalability but allows for focused innovation.
- Parallax's focus on chronic illness management aligns with a healthcare market projected to grow significantly over the next few years.
- The company's proprietary technologies, such as REBOOT and Target System, position it competitively within the digital healthcare landscape.
Who Are PRLX's Competitors?
PRLX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CTBO Cantabio Pharmaceuticals, Inc. | $1.01 | +0.00% | 50 | |
| VEEV Veeva Systems Inc. | $250.53 | -0.19% | $40.7B | 88 |
| GEHC GE HealthCare Technologies Inc. | $74.45 | -0.23% | $33.6B | 61 |
| PMCUF Pro Medicus Limited | $139.96 | +1.55% | $14.6B | 59 |
| BTSG BrightSpring Health Services, Inc. | $59.53 | +0.34% | $11.7B | 83 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $195.62 | -0.45% | $11.5B | 81 |
| HQY HealthEquity, Inc. | $104.27 | +0.31% | $8.72B | 90 |
| HNGE Hinge Health, Inc. | $85.62 | -3.21% | $6.63B | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PRLX's Key Strengths?
Innovative proprietary technologies that address chronic illness management.
- Strong gross margins indicating potential for profitability.
- Focused approach with a small, agile team allows for rapid innovation.
What Are PRLX's Weaknesses?
Current negative profit margin indicates operational challenges.
- Limited workforce may restrict scalability and growth potential.
- Dependence on regulatory approvals for product launches.
What Could Drive PRLX Stock Higher?
Launch of new telehealth solutions targeting chronic illness management.
- Development and testing of proprietary diagnostic technologies.
- Expansion of partnerships with healthcare providers for product integration.
- Regulatory submissions for new healthcare products and services.
- Continuous improvement of existing technologies to enhance patient engagement.
What Are the Key Risks for PRLX?
Regulatory hurdles that could delay product approvals.
- Intense competition from established players in the healthcare technology sector.
- Economic fluctuations impacting healthcare spending and service adoption.
- Operational challenges related to maintaining profitability.
- Limited financial disclosures affecting investor confidence.
What Are the Growth Opportunities for PRLX?
- Growth opportunity 1: The global telehealth market is projected to reach $459.8 billion by 2030, driven by increased adoption of remote healthcare services. Parallax's innovative platforms, such as Fotodigm and REBOOT, position it to capture a significant share of this expanding market, particularly in chronic disease management.
- Growth opportunity 2: The demand for point-of-care diagnostic testing is on the rise, with the market expected to grow at a CAGR of 10.8% through 2027. Parallax's proprietary Target System offers a competitive edge in this space, providing rapid and accurate diagnostic solutions that can enhance patient care and streamline healthcare workflows.
- Growth opportunity 3: As behavioral health becomes increasingly prioritized in healthcare, Parallax's REBOOT technology addresses the need for effective chronic illness management. With the behavioral health market projected to reach $240 billion by 2026, Parallax's solutions could capitalize on this trend, improving patient outcomes and driving revenue growth.
- Growth opportunity 4: The integration of artificial intelligence in healthcare is expected to transform patient care, with the AI healthcare market projected to grow to $188 billion by 2030. Parallax's commitment to leveraging technology for actionable insights positions it favorably to innovate and enhance its product offerings in this evolving landscape.
- Growth opportunity 5: The increasing prevalence of chronic diseases globally presents a significant opportunity for Parallax. With an estimated 1.5 billion people affected by chronic illnesses, the company can expand its reach and impact through targeted solutions that address these pressing healthcare challenges.
What Are PRLX's Competitive Advantages?
- Proprietary technologies that enhance patient engagement and outcomes.
- Strong focus on chronic illness management differentiates Parallax in the market.
- Established relationships with healthcare providers bolster service adoption.
- Innovative product offerings cater to the growing demand for telehealth solutions.
- Expertise in behavioral health technology positions the company competitively.
What Does PRLX Do?
Founded in 2005, Parallax Health Sciences, Inc. has evolved from its original identity as Endeavor Power Corporation to become a key player in the healthcare technology sector. Headquartered in Santa Monica, California, the company specializes in building a comprehensive digital healthcare network that facilitates remote communication, diagnosis, treatment, and monitoring of patients. Parallax offers a range of innovative products, including patent-pending software, mobile applications, and electronic kits designed to address primary health concerns such as diabetes, blood pressure, and cardiovascular issues. Notably, the company's REBOOT technology aims to transform chronic illness management by modifying patient behavior, while its proprietary Target System provides point-of-care diagnostic testing. Parallax's offerings extend to behavioral health products and telehealth solutions, positioning it as a versatile provider in the healthcare landscape. The company's commitment to improving patient outcomes through technology underscores its strategic focus on integrated healthcare solutions, making it a noteworthy entity within the rapidly evolving medical information services industry.
What Products and Services Does PRLX Offer?
- Develops integrated digital healthcare networks for remote patient communication and monitoring.
- Offers patent-pending software and mobile applications for chronic illness management.
- Provides point-of-care diagnostic testing products and services.
- Delivers behavioral health technologies aimed at modifying patient behavior.
- Facilitates telehealth solutions through its Fotodigm platform.
- Offers prescription medication dosage monitoring services.
How Does PRLX Make Money?
- Generates revenue through the sale of proprietary healthcare technology products.
- Monetizes software and mobile applications designed for patient management.
- Offers subscription-based services for remote monitoring and telehealth.
- Collaborates with third-party licensed platforms for additional product offerings.
- Provides diagnostic testing services to healthcare providers and institutions.
What Industry Does PRLX Operate In?
The healthcare information services industry is experiencing rapid growth, driven by increasing demand for remote patient monitoring and digital health solutions. With a market size projected to reach $500 billion by 2028, companies like Parallax Health Sciences, Inc. are well-positioned to capitalize on this trend. The competitive landscape includes various players, but Parallax differentiates itself through its proprietary technologies and integrated service offerings, addressing critical needs in chronic illness management and telehealth.
Who Are PRLX's Key Customers?
- Healthcare providers seeking innovative remote monitoring solutions.
- Patients managing chronic illnesses requiring ongoing support.
- Organizations focused on improving behavioral health outcomes.
- Diagnostic laboratories utilizing point-of-care testing products.
- Telehealth platforms integrating advanced healthcare technologies.
Company Profile
Parallax Health Sciences, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Santa Monica, US. The company is led by CEO Paul R. Arena. PRLX has traded publicly since 2022.
Key Financial Metrics
Return on equity for Parallax Health Sciences, Inc. stands at 158.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Insider Activity
The most recent 12 insider filings for Parallax Health Sciences, Inc. break down as 3 sales and 9 purchases. On net that is roughly 24.8M shares acquired (about $1.3M) — insiders putting money in tends to read as conviction.
PRLX Financials
Bull Case vs Bear Case
Bull Case
- Innovative proprietary technologies that address chronic illness management.
- Strong gross margins indicating potential for profitability.
- Focused approach with a small, agile team allows for rapid innovation.
- Upcoming: Launch of new telehealth solutions targeting chronic illness management.
Bear Case
- Current negative profit margin indicates operational challenges.
- Limited workforce may restrict scalability and growth potential.
- Dependence on regulatory approvals for product launches.
- Potential: Regulatory hurdles that could delay product approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PRLX Latest News
No recent news available for PRLX.
PRLX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PRLX.
Price Targets
Wall Street price target analysis for PRLX.
PRLX MoonshotScore
What does this score mean?
The MoonshotScore rates PRLX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Paul R. Arena
CEO
Paul R. Arena has extensive experience in the healthcare technology sector, having led Parallax Health Sciences since its inception. With a background in business management and healthcare innovation, he has been instrumental in steering the company's strategic direction and product development. His leadership is characterized by a commitment to integrating technology with healthcare solutions to improve patient outcomes.
Track Record: Under Paul R. Arena's leadership, Parallax has developed several proprietary technologies, including REBOOT and the Target System, enhancing its market position. His focus on innovation and operational efficiency has guided the company through various challenges, positioning it for future growth.
PRLX OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers like OTCQX or OTCQB. These companies may have less stringent reporting and disclosure standards, which can affect transparency and investor confidence.
- OTC Tier: OTC Other
- Limited financial disclosures may hinder investor confidence and analysis.
- Low trading volume can lead to high volatility and price fluctuations.
- Regulatory risks associated with healthcare technology approvals.
- Verify the company's financial health through available reports.
- Assess the regulatory status of key products and technologies.
- Evaluate market competition and positioning within the industry.
- Investigate the management team's track record and expertise.
- Monitor industry trends that could impact growth and profitability.
- Established history since 2005, indicating stability in operations.
- Proprietary technologies that are patent-pending, showcasing innovation.
- Engagement with healthcare providers and institutions for product testing.
PRLX Healthcare Stock FAQ
What does Parallax Health Sciences, Inc. do?
Parallax Health Sciences, Inc. specializes in developing integrated digital healthcare solutions that facilitate remote communication, diagnosis, treatment, and monitoring of patients. The company offers a range of products, including proprietary software, mobile applications, and diagnostic testing platforms, aimed at improving chronic illness management and enhancing patient outcomes.
What do analysts say about PRLX stock?
Analysts view PRLX stock with caution due to its current financial challenges, including a negative profit margin. However, the company's innovative technologies and focus on chronic illness management present potential growth opportunities, particularly as the telehealth market expands. Investors may want to evaluate these factors in their analysis.
What are the main risks for PRLX?
The primary risks for Parallax Health Sciences, Inc. include regulatory hurdles that may delay product approvals, intense competition from established healthcare technology firms, and operational challenges related to maintaining profitability. Additionally, limited financial disclosures could impact investor confidence and market perception.
What are the key factors to evaluate for PRLX?
Evaluate PRLX on fundamentals, analyst consensus, and risk factors. Parallax Health Sciences, Inc. presents a unique investment thesis driven by its innovative product offerings and the growing demand for digital healthcare solutions. Not financial advice.
How frequently does PRLX data refresh on this page?
PRLX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PRLX's recent stock price performance?
Parallax Health Sciences, Inc. (PRLX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative proprietary technologies that address chronic illness management. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PRLX overvalued or undervalued right now?
Parallax Health Sciences, Inc. (PRLX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PRLX before investing?
Before investing in Parallax Health Sciences, Inc. (PRLX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis.